Kyowa Hakko establishes translation research lab in Singapore

10 September 2013

Japanese mid-sized drugmaker Kyowa Hakko Kirin (TYO: 41521) has established an international R&D center for biomedical sciences in Singapore, the company said in a web posting.

The new Singapore Translational Research Laboratory (STRL), to be located at the Biopolis, will be operated under the firm’s wholly-owned subsidiary Kyowa Hakko Kirin (Singapore) Pte, that will play a leading role in Kyowa Hakko’s global R&D efforts in translational research.

STRL has initiated a joint collaborative research project with the National University of Singapore and the National University Cancer Institute, Singapore to conduct pre-clinical research on bio-molecular drugs developed by Kyowa Hakko and explore biomarker candidates, which could facilitate and accelerate future clinical trials.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >